Browsing by Subject "Glioblastoma; Neural-progenitor-like -like; Mesenchymal-like; intratumoral heterogeneity."

Glioblastoma is the most aggressive and lethal tumor in the central nervous system. One of the main challenges of current treatment reside in its high intratumoral heterogeneity. Within one tumor, there could be several glioblastoma subtypes which harbor distinct molecular signatures and associated with different clinical properties. For instance, mesenchymal-like glioblastoma patients have the shortest survival time and this subtype is highly resistant to radiation. The current subtype classification heavily relies on transcriptomic analysis, which is not available for every patient due to its high cost. Here, I utilized a polycation reagent to treat neural-progenitor-like and mesenchymal-like glioblastoma cells with increasing concentrations and evaluate their cell viability using luminescence-based CellTiter-GLO assay. I found that neural-progenitor-like glioblastomas cell growth was significantly inhibited at intermediate concentrations of the polymer, while mesenchymal-like glioblastomas were less affected. With polymer concentration increasing, the inhibition effect displays a dose-dependent trend. My results demonstrated that neural-progenitor-like glioblastomas are more sensitive to the polymer than mesenchymal-like ones. The different sensitivity towards the polymer between these two subtypes suggests polymer could be used as a potential reagent to distinguish glioblastoma subtypes.